Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 45

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 45
---
 to the $15.0 billion issuance of senior notes, AbbVie terminated both the bridge and term loan credit agreements in the first quarter of 2024. In February 2024, concurrent with the ImmunoGen acquisition, the company assumed and repaid an ImmunoGen senior secured term loan at a fair value of $99 million.

2025 Form 10-Q | 18

Note 9 Post-Employment BenefitsThe following table summarizes net periodic benefit cost relating to the company’s defined benefit and other post-employment plans:Defined benefit plansOther post- employment plansThree months endedJune 30,Six months endedJune 30,Three months endedJune 30,Six months endedJune 30,(in millions)20252024202520242025202420252024Service cost$68 $71 $131 $143 $10 $10 $20 $21 Interest cost124 113 241 226 11 11 22 21 Expected return on plan assets(208)(196)(414)(393)— — — — Amortization of prior service credit— — — — (9)(9)(18)(18)Amortization of actuarial loss10 13 16 26 2 5 4 9 Net periodic benefit cost (credit)$(6)$1 $(26)$2 $14 $17 $28 $33 

The components of net periodic benefit cost other than service cost are included in other expense, net in the condensed consolidated statements of earnings.

Note 10 EquityStock-Based Compensation

Stock-based compensation expense is principally related to awards issued pursuant to the AbbVie 2013 Incentive Stock Program and the AbbVie Amended and Restated 2013 Incentive Stock Program and is summarized as follows:Three months endedJune 30,Six months endedJune 30,(in millions)2025202420252024Cost of products sold$11 $10 $33 $32 Research and development79 74 239 207 Selling, general and administrative89 134 317 327 Pre-tax compensation expense179 218 589 566 Tax benefit(34)(34)(104)(94)After-tax compensation expense$145 $184 $485 $472 In addition to stock-based compensation expense included in the table above and in connection